Aug 13, 2020
MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President
Aug 13, 2020
Lynda Tussey, PhD joins Vaxess Technologies as Chief Development Officer
Aug 13, 2020
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
Aug 13, 2020
Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates
Aug 12, 2020
Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Aug 12, 2020
Potential Enhancement of Prostate Cancer Treatment Options: First Patient Randomized in Phase III Trial
Aug 12, 2020
Akero Therapeutics Reports Second Quarter 2020 Financial Results
Aug 11, 2020
JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials
Aug 11, 2020
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
Jun 18, 2020
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration
Jun 18, 2020
Wider Range of Prospective Patients in the UK, Canada and the US for Continued Clinical Study
Jun 16, 2020
TrialSpark announces launch of Project Covalence, a clinical trial platform to rapidly test drugs and diagnostics for COVID-19
Jun 16, 2020
Signant Health Expands Its Pioneering Patient Engagement App, TrialGuide, to Enable Remote Participation in Global Clinical Trials
Jun 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 15, 2020
Soliton Reports Positive Pivotal Cellulite Clinical Trial Results
Jun 15, 2020
New Research Sheds Light on Intentional Non-adherence in Clinical Trials
Jun 15, 2020
Koneksa Joins the Critical Path Institute ePRO Consortium
Jun 15, 2020
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use
Jun 10, 2020
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
Jun 10, 2020
COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator